Clinical trials: Clear Cell Kidney Cancer
Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors.
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma
- Trial name
- NCT00335556
- Testing
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 291 people
- Sponsor
- Children's Oncology Group
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
This study is A prospective，single arm, multicenter clinical study of BTLA monoclonal antibody JS004 (B/T lymphocyte attenuator factor monoclonal antibody) in combination with toripalimab in patients with unresectable or advanced…
- Trial name
- NCT06730932
- Testing
- JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
- Where
- China
- Volunteers
- 31 people
- Sponsor
- RenJi Hospital
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer
Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
This pilot phase 0 trial studies how well enzalutamide works before surgery in treating patients with kidney cancer. Androgens are a type of hormone produced by the body that may cause kidney tumors to grow.
- Trial name
- NCT02885649
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Nephrectomy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rutgers, The State University of New Jersey
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Clear Cell Renal Cell Carcinoma
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment
Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.
- Trial name
- IPSOC (NCT02247583)
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- KU Leuven
Renal Cell Carcinoma
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer.
- Trial name
- NCT01399918
- Testing
- everolimus and bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Kidney Cancer
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00589550
- Testing
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thomas Olencki
Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth or by blocking blood flow to the tumor.
- Conditions
- Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT00098618
- Testing
- sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma
Combination of Toripalimab and JS004 Therapy for ccRCC
This study is a single center, prospective, randomized controlled phase II clinical trial aimed at examining the efficacy and safety of the combination of toripalimab and JS004 versus standard therapy for second-line treatment of…
- Trial name
- NCT06690697
- Testing
- JS004, Toripalimab, Axitinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Immunotherapy, Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
The primary objective of this study is to develop and train the Elephas live tumor diagnostic platform and determine the ex-vivo accuracy of the Elephas Score using in-vivo RECIST 1.1 as the reference method
- Conditions
- Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder
- Trial name
- ELEPHAS-02 (NCT05520099)
- Testing
- Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
- Where
- 12 sites in United States
- Volunteers
- 416 people
- Sponsor
- Elephas
Kidney Cancer
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also block blood flow to the tumor.
- Trial name
- NCT00331409
- Testing
- Everolimus, imatinib mesylate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Pediatric Solid Tumor, Osteosarcoma
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old…
- Conditions
- Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma
- Trial name
- NCT04897321
- Testing
- Fludarabine, Cyclophosphamide, MESNA
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- St. Jude Children's Research Hospital
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well they work compared to sorafenib alone in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT00126594
- Testing
- Sorafenib Tosylate, Recombinant Interferon Alfa-2b, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
The aim of this study is to identify and/or validate biomarkers and imaging markers to predict and monitor the activity of a new class of therapeutic agents called antiangiogenics for the treatment of metastatic renal cell…
- Trial name
- PREINSUT (NCT00930345)
- Testing
- Sunitinib (SUTENT)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma, Clear Cell
A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma
The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of…
- Trial name
- NCT06656039
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- RenJi Hospital
Select Advanced Malignancies, Kidney Cancer
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Participants with Select Advanced Malignancies.
- Conditions
- Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
- Trial name
- NCT02118337
- Testing
- MEDI0680, Durvalumab, Nivolumab
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 97 people
- Sponsor
- MedImmune LLC
Non-clear Renal Cell Carcinoma
Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
The goal of this prospective, multicenter, single-arm clinical study is to evaluate the efficacy and safety of toripalimab in combination with axitinib for postoperative adjuvant therapy for non-clear renal cell carcinoma with…
- Trial name
- IUNU-RC (NCT05768464)
- Testing
- Toripalimab, Axitinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
This randomized, multicenter,open-label, phase II study is to evaluate the effects of PD-1 inhibitor combination with autologous cytokine-induced killer cell immunotherapy in the second-line treatment of patients with metastatic…
- Trial name
- NCT03987698
- Testing
- SHR-1210, CIK cells
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital